

| Division: Pharmacy Policy  | Subject: Prior Authorization Criteria |
|----------------------------|---------------------------------------|
| Original Development Date: | July 1, 2025                          |
| Original Development Date: | July 1, 2023                          |
| Revision Date:             |                                       |

## **Neffy®** (epinephrine nasal spray)

## **LENGTH OF AUTHORIZATION**: 1 year

## **REVIEW CRITERIA**:

- Patient must be  $\geq$  4 years of age and weigh  $\geq$  15 kg; **AND**
- Patient has diagnosis of an allergy that may require emergency treatment; AND
- Prescriber attests the patient does not have a nasal condition such as nasal polyps or history of nasal surgery.

## **DOSING AND ADMINISTRATION:**

- Refer to product labeling at <a href="https://www.accessdata.fda.gov/scripts/cder/daf/">https://www.accessdata.fda.gov/scripts/cder/daf/</a>
- Available as 1 mg/0.1 mL and 2 mg/0.1 mL epinephrine/spray nasal spray

